Novel synthetic molecules targeting the bacterial RNA polymerase assembly

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 245-251

  André, Estelle ^a   Bastide, Lionel ^b   Michaux Charachon, Sylvie ^c,d   Gouby, Anne ^d   Villain Guillot, Philippe ^a   Latouche, Jaqueline ^a   Bouchet, Aurélie ^a   Gualtiéri, Maxime ^b   Leonetti, Jean Paul ^a  

^a CNRS   (France)

^b Selectbiotics   (France)

^c INSERM   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Anti infective agents; Antibacterial drug screening; Antibacterials; Antibiotic resistance; Transcription

Indexed keywords

3 (DODECYLDIMETHYLAMMONIO) 1 PROPANESULFONIC ACID; AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL RNA; CEFAZOLIN; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; NORFLOXACIN; OFLOXACIN; OXACILLIN; PEFLOXACIN; PENICILLIN G; PIPERACILLIN; PRISTINAMYCIN; RIFAMPICIN; RNA POLYMERASE; SB 2; SB 4; SB 5; SB 7; SB 8; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACTERIUM ISOLATE; BIOASSAY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; PROTEIN PROTEIN INTERACTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ANALYSIS;

EID: 31544454456     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki426     Document Type: Article

References (26)

1. Campbell EA, Korzheva N, Mustaev A et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901-12.
2. O'Neill A, Oliva B, Storey C et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 3163-6.
3. Darst SA. New inhibitors targeting bacterial RNA polymerase. Trends Biochem Sci 2004; 29: 159-60.
4. Oneyama C, Nakano H, Sharma SV. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 2002; 21: 2037-50.
5. Dragic T, Trkola A, Thompson DA et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000; 97: 5639-44.
6. 3. J Am Chem Soc 2001; 123: 1280-8.
7. Welzenbach K, Hommel U, Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 2002; 277: 10590-8.
8. Sharp MM, Chan CL, Lu CZ et al. The interface of sigma with core RNA polymerase is extensive, conserved, and functionally specialized. Genes Dev 1999; 13: 3015-26.
9. Gribskov M, Burgess RR. Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins. Nucleic Acids Res 1986; 14: 6745-63.
10. Achberger EC, Whiteley HR. The interaction of Escherichia coli core RNA polymerase with specificity-determining subunits derived from unmodified and SP82-modified Bacillus subtilis RNA polymerase. J Biol Chem 1980; 255: 11957-64.
11. Chen YF, Helmann JD. Restoration of motility to an Escherichia coli fliA flagellar mutant by a Bacillus subtilis sigma factor. Proc Natl Acad Sci USA 1992; 89: 5123-7.
12. Deora R, Misra TK. Characterization of the primary sigma factor of Staphylococcus aureus. J Biol Chem 1996; 271: 21828-34.
13. WhiG form of RNA polymerase transcribes a gene encoding a ProX-like protein that is dispensable for sporulation. Gene 1998; 212: 137-46.
14. Andre E, Bastide L, Villain-Guillot P et al. A multiwell assay to isolate compounds inhibiting the assembly of the prokaryotic RNA polymerase. Assay Drug Dev Technol 2004; 2: 629-35.
15. Rouby J, Pugniere M, Mani JC et al. Characterization of monoclonal antibodies against Escherichia coli core RNA polymerase. Biochem J 2002; 361: 347-54.
16. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Sixth Edition: Approved Standard M07-A6. NCCLS, Villanova, PA, USA, 2003.
17. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Sixth Edition: Approved Standard M100-S15. NCCLS, Villanova, PA, USA, 2003.
18. Sergio S, Pirali G, White R et al. Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J Antibiot (Tokyo) 1975; 28: 543-9.
19. Oliva B, O'Neill A, Wilson JM et al. Antimicrobial properties and mode of action of the pyrrothine holomycin. Antimicrob Agents Chemother 2001; 45: 532-9.
20. 70. Cell 2001; 7: 935-44.
21. 70 factor induced by binding to the core enzyme. J Biol Chem 1998; 273: 32995-3001.
22. Bergendahl V, Heyduk T, Burgess RR. Luminescence resonance energy transfer-based high-throughput screening assay for inhibitors of essential protein-protein interactions in bacterial RNA polymerase. Appl Environ Microbiol 2003; 69: 1492-8.
23. Artsimovitch I, Chu C, Lynch AS et al. A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science 2003; 302: 650-4.
24. Lancini GC, Sartori G. Rifamycins LXI: In vivo inhibition of RNA synthesis of rifamycins. Experientia 1968; 24: 1105-6.
25. Artsimovitch I, Vassylyeva MN, Svetlov D et al Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 2005, 122: 351-63.
26. Zervosen A, Lu WP, Chen Z et al. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob Agents Chemother 2004; 48: 961-9.